Lack of nigrostriatal pathology in a rat model of proteasome inhibition
Authors:
- Amy B. Manning-BoğAMAmy B. Manning-Boğ
- Vivian P. ChouVCVivian P. Chou
- Jennifer JohnstonJJJennifer Johnston
- Donato A. Di MonteDMDonato A. Di Monte
- 21 July 2006
- journal article
- editorial
- Published by Wiley in Annals of Neurology
- Vol. 60 (2) , 256-260
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- Proteasomal inhibition causes loss of nigral tyrosine hydroxylase neuronsAnnals of Neurology, 2006
- Reproducible nigral cell loss after systemic proteasomal inhibitor administration to ratsAnnals of Neurology, 2006
- The proteasomal inhibition model of Parkinson's disease: “Boon or bust”?Annals of Neurology, 2006
- Proteasome inhibition and Parkinson's disease modelingAnnals of Neurology, 2006
- Proteasome inhibitor-induced model of Parkinson's diseaseAnnals of Neurology, 2006
- Failure of proteasome inhibitor administration to provide a model of Parkinson's disease in rats and monkeysAnnals of Neurology, 2006
- Ubiquitin–proteasome system and Parkinson's diseasesExperimental Neurology, 2005
- Systemic exposure to proteasome inhibitors causes a progressive model of Parkinson's diseaseAnnals of Neurology, 2004
- Filamentous α-synuclein inclusions link multiple system atrophy with Parkinson's disease and dementia with Lewy bodiesNeuroscience Letters, 1998
- A Semiautomated Analysis Method for Catecholamines, Indoleamines, and Some Prominent Metabolites in Microdissected Regions of the Nervous System: An Isocratic HPLC Technique Employing Coulometric Detection and Minimal Sample PreparationJournal of Neurochemistry, 1986